Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective phase IIb study of AADC gene therapy in patients with aromatic L-amino acid decarboxylase (AADC) deficiency

Trial Profile

Prospective phase IIb study of AADC gene therapy in patients with aromatic L-amino acid decarboxylase (AADC) deficiency

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eladocagene exuparvovec (Primary)
  • Indications Aromatic amino acid decarboxylase deficiency; Inborn error amino acid metabolic disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2024 According to an Agilis Biotherapeutics media release, The Company announced the submission of a BLA to the U.S. FDA
    • 03 Oct 2017 According to an Agilis Biotherapeutics media release, The Company may extend the Phase IIb study to permit the treatment of additional patients in need of therapeutic intervention while it undertakes activities in support of the approval of AGIL-AADC in multiple countries around the world.
    • 03 Oct 2017 According to an Agilis Biotherapeutics media release, dosing of the last of six planned patients has been completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top